Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 13, 2021

SELL
$2.41 - $7.11 $152,509 - $449,935
-63,282 Reduced 82.13%
13,767 $35,000
Q1 2021

May 12, 2021

SELL
$4.7 - $7.17 $26,517 - $40,453
-5,642 Reduced 6.82%
77,049 $467,000
Q4 2020

Feb 11, 2021

BUY
$2.95 - $11.04 $5,091 - $19,055
1,726 Added 2.13%
82,691 $492,000
Q3 2020

Nov 16, 2020

BUY
$9.37 - $12.06 $468,275 - $602,710
49,976 Added 161.27%
80,965 $877,000
Q2 2020

Aug 14, 2020

BUY
$8.29 - $11.47 $136,130 - $188,348
16,421 Added 112.72%
30,989 $334,000
Q4 2018

Feb 12, 2019

BUY
$2.1 - $5.6 $30,592 - $81,580
14,568 New
14,568 $79,000

About AVENUE THERAPEUTICS, INC.


  • Ticker ATXI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 4,127,720
  • Market Cap $13.8M
  • Description
  • Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was in...
More about ATXI
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.